Bellicum Pharmaceuticals, Inc.(NASDAQ : BLCM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||0.84%||612.49||2.6%||$526.18m|
|VRTX||Vertex Pharmaceuticals, Inc.||3.19%||292.55||1.9%||$516.29m|
|GILD||Gilead Sciences, Inc.||0.80%||63.08||1.0%||$513.27m|
|SNSS||Sunesis Pharmaceuticals, Inc.||9.63%||2.96||0.7%||$206.91m|
|CRSP||CRISPR Therapeutics AG||2.78%||66.96||0.6%||$173.29m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.72%||86.85||4.2%||$121.28m|
|EXAS||EXACT Sciences Corp.||6.89%||45.15||17.7%||$107.32m|
|IOVA||Iovance Biotherapeutics, Inc.||0.19%||10.35||0.0%||$103.94m|
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.